PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
187.54%
Cash & equivalents growing 187.54% while TRVN's declined -19.53%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
187.23%
Below half of TRVN's -5.74%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
168.93%
Below half of TRVN's -4.72%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-20.60%
Below half TRVN's 6.67%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.19%
≥ 1.5x TRVN's -8.05%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
164.96%
Below half of TRVN's -4.74%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-45.35%
Above 1.5x TRVN's -27.40%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-33.08%
Higher Short-Term Debt Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
43.64%
Higher Deferred Revenue (Current) Growth compared to TRVN's zero value, indicating better performance.
-68.51%
50-75% of TRVN's -97.58%. Bruce Berkowitz notes a more controlled liability line.
-61.96%
Less than half of TRVN's 74.13%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-61.96%
Less than half of TRVN's 76.31%. David Dodd sees far fewer liability expansions relative to competitor.
19.13%
Above 1.5x TRVN's 0.27%. Michael Burry suspects heavy new equity expansion or dilution.
-3.37%
Below half TRVN's -9.80%. Michael Burry suspects major net losses or high dividends vs. competitor.
-26.34%
Less than half of TRVN's 142.46%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
955.36%
Below half TRVN's -12.21%. Michael Burry sees potential underperformance in building shareholder capital.
164.96%
Below half TRVN's -4.74%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-33.08%
Above 1.5x TRVN's -4.01%. Michael Burry sees a major jump. Investigate leverage rationale.
-197.28%
Less than half of TRVN's 20.34%. David Dodd sees better deleveraging or stronger cash buildup than competitor.